Abstract:Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are the most prevalent forms of the chronic and progressive pathological condition known as cardiomyopathy. These diseases have different aetiologies; however, they share the feature of haemodynamic abnormalities, which is mainly due to dysfunction in the contractile proteins that make up the contractile unit known as the sarcomere. To date, pharmacological treatment options are not disease-specific and rather focus on managing the symptoms, without addressing the disease mechanism. Earliest attempts at improving cardiac contractility by modulating the sarcomere indirectly (inotropes) resulted in unwanted effects. In contrast, targeting the sarcomere directly, aided by high-throughput screening systems, could identify small molecules with a superior therapeutic value in cardiac muscle disorders. Herein, an extensive literature review of 21 small molecules directed to five different targets was conducted. A simple scoring system was created to assess the suitability of small molecules for therapy by evaluating them in eight different criteria. Most of the compounds failed due to lack of target specificity or poor physicochemical properties. Six compounds stood out, showing a potential therapeutic value in HCM, DCM or heart failure (HF). Omecamtiv Mecarbil and Danicamtiv (myosin activators), Mavacamten, CK-274 and MYK-581 (myosin inhibitors) and AMG 594 (Ca2+-sensitiser) are all small molecules that allosterically modulate troponin or myosin. Omecamtiv Mecarbil showed limited efficacy in phase III GALACTIC-HF trial, while, results from phase III EXPLORER-HCM trial were recently published, indicating that Mavacamten reduced left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction and improved the health status of patients with HCM. A novel category of small molecules known as “recouplers” was reported to target a phenomenon termed uncoupling commonly found in familial cardiomyopathies but has not progressed beyond preclinical work. In conclusion, the contractile apparatus is a promising target for new drug development.

A systematic review of present and future pharmaco‐structural therapies for hypertrophic cardiomyopathy

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review

Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond

The Revolution of Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy

Novel Pharmacotherapy in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies

Obstructive hypertrophic cardiomyopathy: a review of new therapies

Medical Treatment Strategies for Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in Hypertrophic Cardiomyopathy

Considerations for drug trials in hypertrophic cardiomyopathy

Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review

Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon?

Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside

Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten

An overview of the treatments for hypertrophic cardiomyopathy

Non-pharmaceutical Interventions for Hypertrophic Cardiomyopathy: A Mini Review

Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment